PMID- 25623082
OWN - NLM
STAT- MEDLINE
DCOM- 20160607
LR  - 20150903
IS  - 1365-2885 (Electronic)
IS  - 0140-7783 (Linking)
VI  - 38
IP  - 5
DP  - 2015 Oct
TI  - The safety of high-dose buprenorphine administered subcutaneously in cats.
PG  - 434-42
LID - 10.1111/jvp.12203 [doi]
AB  - The safety of a proprietary formulation of buprenorphine hydrochloride 
      administered subcutaneously (SC) to young cats was investigated in a blinded, 
      randomized study. Four cohorts of eight cats aged approximately 4 months were 
      administered saline, 0.24, 0.72 or 1.20 mg/kg/day buprenorphine SC for nine 
      consecutive days, representing 0x, 1x, 3x and 5x of the intended dose. Cats were 
      monitored daily for evidence of clinical reactions, food and water intake and 
      adverse events (AEs). Physical examinations, clinical pathology, vital signs and 
      electrocardiograms (ECGs) were evaluated at protocol-specified time points. 
      Complete necropsy and histopathologic examinations were performed following 
      humane euthanasia. Four buprenorphine-treated cats experienced AEs during the 
      study, two unrelated and two related to study drug administration. The two cats 
      with AEs considered related to drug administration had clinical signs of 
      hyperactivity, difficulty in handling, disorientation, agitation and dilated 
      pupils in one 0.24 mg/kg/day cat and one 0.72 mg/kg/day cat. All of these 
      clinical signs were observed simultaneously. There were no drug-related effects 
      on survival, injection response, injection site inspections, body weight, food or 
      water consumption, bleeding time, urinalysis, respiration rate, heart rate, ECGs, 
      blood pressures, body temperatures, macroscopic examinations or organ weights. 
      Once daily buprenorphine s.c. injections at doses of 0.24, 0.72 and 1.20 
      mg/kg/day for 9 consecutive days were well tolerated in young domestic cats.
CI  - (c) 2015 The Authors. Journal of Veterinary Pharmacology and Therapeutics Published 
      by John Wiley & Sons Ltd.
FAU - Sramek, M K
AU  - Sramek MK
AD  - Abbott Laboratories, Abbott Park, IL, USA.
FAU - Haas, M C
AU  - Haas MC
AD  - WIL Research, Ashland, OH, USA.
FAU - Coleman, G D
AU  - Coleman GD
AD  - WIL Research, Ashland, OH, USA.
FAU - Atterson, P R
AU  - Atterson PR
AD  - WIL Research, Ashland, OH, USA.
FAU - Hamlin, R L
AU  - Hamlin RL
AD  - QTest Labs, LLC, Columbus, OH, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150127
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - 0 (Analgesics, Opioid)
RN  - 40D3SCR4GZ (Buprenorphine)
SB  - IM
MH  - Analgesics, Opioid/administration & dosage/*adverse effects
MH  - Animals
MH  - Behavior, Animal/drug effects
MH  - Blood Coagulation/drug effects
MH  - Buprenorphine/administration & dosage/*adverse effects
MH  - Cats
MH  - Confusion/chemically induced
MH  - Diarrhea/chemically induced/veterinary
MH  - Drinking/drug effects
MH  - Eating/drug effects
MH  - Female
MH  - Hyperkinesis/chemically induced
MH  - Injections, Subcutaneous/veterinary
MH  - Male
EDAT- 2015/01/28 06:00
MHDA- 2016/06/09 06:00
CRDT- 2015/01/28 06:00
PHST- 2014/06/13 00:00 [received]
PHST- 2014/12/20 00:00 [accepted]
PHST- 2015/01/28 06:00 [entrez]
PHST- 2015/01/28 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - 10.1111/jvp.12203 [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2015 Oct;38(5):434-42. doi: 10.1111/jvp.12203. Epub 2015 
      Jan 27.